Skip to Main Content


Skip Nav Destination

Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)

Cancer Res (2021) 81 (13_Supplement): CT187.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • A. Yu. Pavlov
  • A. G. Dzidzariya
  • R. A. Gafanov
  • I. I. Khalil'
  • A. R. Vashurin
Cancer Urology (2022) 17 (4): 124.
Close Modal

or Create an Account

Close Modal
Close Modal